Dutch-German VC firm Forbion has raised over a quarter-billion euros for its flagship Forbion IV fund, designed mainly for EU and UK investments. Around 20% will be targeted at North American startups.
The company says it will build a portfolio of approximately 15 companies, of which ten will be existing “growth” opportunities and five will be new companies, either founded or co-founded by Forbion.
Managing partner Sander Slootweg said, “The success of our first close not only reflects Forbion’s consistent delivery of upper quartile returns but also its clear vision and proprietary methodology for identifying new prospects.”
“We continue to see the opportunities for superior returns, in part due to the ongoing undersupply of capital for European development-stage life sciences investment and its non-cyclical nature.”
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze